148 related articles for article (PubMed ID: 17098957)
1. Multitherapy for diabetes.
Vos E
CMAJ; 2006 Nov; 175(10):1246-7; author reply 1247. PubMed ID: 17098957
[No Abstract] [Full Text] [Related]
2. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
Bajaj M; Jialal I
Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
[No Abstract] [Full Text] [Related]
3. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
Båvenholm P; Attvall S; Nilsson PM
Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
[No Abstract] [Full Text] [Related]
4. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
[No Abstract] [Full Text] [Related]
5. [On behalf and the extent of evidence].
Ruiz J
Rev Med Suisse; 2010 Jun; 6(252):1171-2. PubMed ID: 20614750
[No Abstract] [Full Text] [Related]
6. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
[No Abstract] [Full Text] [Related]
7. Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients.
Lakatos J; Molnár M; Tóth K
Acta Physiol Hung; 1996; 84(4):433-5. PubMed ID: 9328624
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
9. [Atherogenic dyslipidaemia in type 2 diabetes].
Zozulińska D
Kardiol Pol; 2006 Oct; 64(10 Suppl 6):S567-71. PubMed ID: 20527378
[TBL] [Abstract][Full Text] [Related]
10. ACCORD and Risk-Factor Control in Type 2 Diabetes.
Nilsson PM
N Engl J Med; 2010 Apr; 362(17):1628-30. PubMed ID: 20228405
[No Abstract] [Full Text] [Related]
11. Dyslipidaemia in diabetes.
Patel J
Clin Evid; 2006 Jun; (15):555-75. PubMed ID: 16973026
[No Abstract] [Full Text] [Related]
12. Combination therapy in the management of mixed dyslipidaemia.
Cannon CP
J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
[TBL] [Abstract][Full Text] [Related]
13. Multitherapy for diabetes.
Harris SB
CMAJ; 2006 Nov; 175(10):1247-8. PubMed ID: 17098959
[No Abstract] [Full Text] [Related]
14. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
15. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
Olsson AG
Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
[No Abstract] [Full Text] [Related]
16. [Is it necessary to systematically treat diabetics with statins?].
Vergès B
Journ Annu Diabetol Hotel Dieu; 2001; ():189-95. PubMed ID: 11565462
[No Abstract] [Full Text] [Related]
17. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
18. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
Sacks FM
Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
[No Abstract] [Full Text] [Related]
19. Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes.
Sirois C; Moisan J; Poirier P; Grégoire JP
Diabetes Care; 2007 Jul; 30(7):1880-2. PubMed ID: 17384345
[No Abstract] [Full Text] [Related]
20. What to make of ACCORD. Surprising new results from the landmark diabetes study.
Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):1-2, 7. PubMed ID: 20848750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
